BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by research analysts at Needham & Company LLC from $14.00 to $15.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside of 107.47% from the company’s current price.

Several other equities analysts also recently issued reports on BCRX. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.17.

BioCryst Pharmaceuticals Trading Down 8.8 %

Shares of BCRX opened at $7.23 on Monday. The stock has a 50 day simple moving average of $7.60 and a 200-day simple moving average of $7.60. The stock has a market cap of $1.50 billion, a PE ratio of -11.85 and a beta of 1.76. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. The business’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.19) earnings per share. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of BCRX. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. Quantinno Capital Management LP bought a new position in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $82,000. DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter worth $74,000. Xponance Inc. boosted its position in BioCryst Pharmaceuticals by 13.1% in the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 1,505 shares during the last quarter. Finally, SkyView Investment Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 3,000 shares during the period. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.